FDA Opens Docket on Ibogaine Trials for PTSD and Opioid Addiction

The Food and Drug Administration opened a public docket on Oct. 6 asking researchers, clinicians, patients and the public how the first federally funded clinical trials of ibogaine should be designed — a compound with a devoted following among veterans, a long history of unsanctioned use and a documented ability to disrupt the heart's rhythm.

Comments are due Nov. 20 on Docket No. FDA-2026-N-10429. In the notice, the agency says the Department of Health and Human Services is already paying for ibogaine's clinical development, and that the first federally supported trials are expected to study the drug in adults with opioid use disorder and adults with post-traumatic stress disorder.

What the agency is asking

The FDA wants input on the parts of an ibogaine trial it considers hardest to get right: dose selection and escalation, the care setting, safety monitoring, eligibility criteria, stopping rules and safety oversight. Those answers will shape how the agency reviews Investigational New Drug applications — the paperwork that lets human research begin — and the notice builds on the final guidance for industry the FDA issued in July, "Psychedelic Drugs: Considerations for Clinical Investigations."

The agency framed the request as a way to move forward without pretending the risks are settled. "The Food and Drug Administration is describing the approaches it is considering for the design of early-phase clinical trials of ibogaine drug products and is opening a public docket to receive comments," it wrote, adding that it is seeking public input "in part, because the Federal Government is funding work in this area."

A narrow safety margin

The FDA's own description of ibogaine's risks is blunt. The drug commonly causes substantial prolongation of the QT interval — a change in the heart's electrical cycle — which has been linked to a life-threatening ventricular arrhythmia called torsades de pointes. In nonclinical studies, rodents and other species showed dose-dependent neurotoxicity, from tremors and loss of coordination at lower doses to seizures and death at higher ones. In a prospective study of patients with opioid use disorder who received a single 10 mg/kg dose, all participants experienced severe transient ataxia, the notice notes.

"FDA has identified serious safety risks with ibogaine drug products that have the potential for exposing human subjects to an unreasonable and significant risk of illness or injury," the agency wrote.

One consequence is that the question of a safe dose remains open. The FDA points out that for drugs that prolong the QT interval, 500 milliseconds is the threshold above which most drug-induced arrhythmias occur, and is conventionally used as a stopping point in drug development. Ibogaine, though, is typically given as a single dose rather than daily, which leaves room for a tradeoff: a repeat dose might still be defensible if the patient is monitored closely enough. The agency cites ibutilide, an approved antiarrhythmic that causes torsades in about 1.7 percent of patients and must be given under continuous electrocardiography for at least four hours, as a rough model — while noting that ibogaine has an active metabolite and would likely require longer monitoring.

The agency also revisits a question its Drug Abuse Advisory Committee first took up in 1993: whether a dose exists that is high enough to help patients but low enough to avoid brain injury. According to the notice, that question "remains unresolved," in part because published studies rarely report the blood levels needed to compare exposures across species.

The design the FDA has in mind

The agency's preliminary thinking, it says, is an initial open-label trial in which small groups of participants each receive a single dose of ibogaine, with the dose rising from one group to the next, administered in an intensively monitored inpatient setting. Data from that first study could then determine whether — and under what conditions — repeat dosing could be tested.

The notice is explicit about its limits. It establishes no legally enforceable requirements, does not represent the agency's final views and, the FDA writes, "predetermines" nothing about any eventual application.

Why veterans are at the center of it

Ibogaine's political momentum is inseparable from veterans' mental health. Executive Order 14401, signed April 18, 2026, directs federal agencies to accelerate research and appropriate approvals for psychedelic drugs to treat serious mental illness, and it singles out ibogaine compounds as showing potential for patients whose conditions persist after standard therapy. The Department of Veterans Affairs has said it is involved in 20 active clinical trials of psychedelic therapies, and VA research puts the lifetime prevalence of PTSD at about 7 percent among veterans, higher than the general population.

New evidence landed the same week the docket opened. Stanford Medicine researchers published one-year follow-up results on 30 special forces veterans with traumatic brain injuries who had traveled to Mexico for ibogaine treatment, 23 of whom had a PTSD diagnosis. Nineteen achieved remission within days, and a month after treatment the group's PTSD symptoms had improved by an average of 88 percent, depression by 87 percent and anxiety by 81 percent. Among the 25 veterans who completed the one-year follow-up, the likelihood of sustained remission at 12 months was 84 percent for PTSD, 66 percent for depression and 61 percent for anxiety among those who had remitted early. The paper appeared Aug. 12 in Translational Psychiatry; Stanford described the findings in a blog post on Oct. 6.

"Over the course of the year, there were improvements that weren't just rapid, but surprisingly sustained for what we normally see in psychiatry," said Camarin Rolle, a clinical assistant professor of psychiatry and behavioral sciences at Stanford and a co-senior author of the study. "We saw persistent reductions in PTSD, depression, anxiety and functional disability."

The researchers are careful about what the study can support. It was observational, not a randomized trial, so it cannot separate ibogaine's effect from everything else that happened during the year: 12 participants received therapy or counseling, three took psychotropic medications, and 23 used at least one psychedelic substance, most often 5-MeO-DMT. Participants also received magnesium infusions alongside the ibogaine to guard against cardiac complications.

What happens next

The FDA has already allowed an early-phase study of noribogaine hydrochloride, a derivative of ibogaine, to proceed as a potential treatment for alcohol use disorder. It says the Advanced Research Projects Agency for Health is funding a program to gather safety and efficacy data through early-phase trials, while the National Institute on Drug Abuse is funding ibogaine research for opioid use disorder, and that the resulting data will be shared publicly with investigators and sponsors.

None of this changes ibogaine's legal status. It remains a Schedule I controlled substance with no approved medical use in the United States — a category reserved for drugs with no accepted medical use and a high potential for abuse. The docket will shape something narrower and more concrete: the conditions under which the government's own trials can begin.

Whether ibogaine eventually joins the approved toolkit for opioid use disorder and post-traumatic stress disorder depends on studies that, for now, exist mostly on paper. Until Nov. 20, anyone with data or an opinion on how to run them can put it on the record.